Eli Lilly And Company  (LLY)
Other Ticker:  

Eli Lilly's



LLY Sales vs. its Competitors Q3 2021

Comparing the results to its competitors, Eli Lilly reported Total Revenue increase in the 3 quarter 2021 by 17.98 % year on year.
The revenue growth was below Eli Lilly's competitors average revenue growth of 46.07 %, recorded in the same quarter.

List of LLY Competitors

With net margin of 16.39 % company reported lower profitability than its competitors.

More on LLY Margin Comparisons

Revenue Growth Comparisons

Net Income Comparison

Eli Lilly And Company Net Income in 3 quarter 2021 declined year on year by -8.13 %, despite income growth by most of its competitors

<<  More on LLY Income Comparisons

Eli Lilly's Comment on Competitors and Industry Peers

Our human pharmaceutical products compete globally with products of many other companies in highly competitive markets. Our animal health products compete globally with products of animal health care companies as well as pharmaceutical, chemical, and other companies that operate animal health businesses.
Important competitive factors for both human pharmaceutical and animal health products include effectiveness, safety, and ease of use; price and demonstrated cost-effectiveness; marketing effectiveness; and research and development of new products and processes. Most new products that we introduce must compete with other branded or generic products already on the market or products that are later developed by competitors. If competitors introduce new products or delivery systems with therapeutic or cost advantages, our products can be subject to decreased sales, progressive price reductions, or both.

We believe our long-term competitive success depends upon discovering and developing (either alone or in collaboration with others) or acquiring innovative, cost-effective human pharmaceutical and animal health products that provide improved outcomes and deliver value to payers, together with our ability to continuously improve the productivity of our operations in a highly competitive environment. There can be no assurance that our research and development efforts will result in commercially successful products, and it is possible that our products will become uncompetitive from time to time as a result of products developed by our competitors.

Generic Pharmaceuticals
One of the biggest competitive challenges we face is from generic pharmaceuticals. In the U.S. and the EU, the regulatory approval process for human pharmaceuticals (other than biological products (biologics)) exempts generics from costly and time-consuming clinical trials to demonstrate their safety and efficacy, allowing generic manufacturers to rely on the safety and efficacy of the innovator product. Therefore, generic manufacturers generally invest far less than we do in research and development and can price their products much lower than our branded products. Accordingly, when a branded non-biologic human pharmaceutical loses its market exclusivity, it normally faces intense price competition from generic forms of the product. In many countries outside the U.S., intellectual property protection is weak and we must compete with generic or counterfeit versions of our products. Many of our animal health products also compete with generics.


Overall company Market Share Q3 2021

Despite strong revenue increase of 17.98 % in Overall company, Eli Lilly lost market share, to approximate 5.13 %.

<<  More on LLY Market Share.

*Market share calculated with total revenue.

LLY's vs. Competition, Data

(Revenue and Income for Trailing 12 Months, in Millions of $, except Employees)

Eli Lilly And Company 27,759 237,145 5,972 39,135
Bristol Myers Squibb Co 45,468 126,660 -5,385 25,000
Johnson and Johnson 91,446 425,844 17,880 126,500
Merck and Co Inc 49,150 200,847 7,211 70,000
Mylan N v 16,861 8,208 266 25,000
Pfizer Inc 69,337 309,150 19,239 78,300
Wyeth 0 0 0 0
Abbott Laboratories 42,308 225,199 7,244 77,000
Watson Pharmaceuticals Inc 0 0 0 0
Cephalon, Inc. 0 0 0 0
Actavis Plc 10,573 3,730 -751 19,200
Amgen Inc 32,341 114,621 5,609 17,900
Procter and Gamble Co 79,242 377,361 15,521 110,000
Celgene Corp 16,982 78,961 1,834 6,012
Patterson Companies Inc 6,281 3,108 165 7,000
Petvivo Holdings Inc 0 20 -3 4
Abbvie Inc 55,169 207,038 7,542 26,000
Hospira Inc 6,921 0 -8 0
Gilead Sciences Inc 27,482 88,681 7,369 7,000
SUBTOTAL 577,320 2,406,573 89,705 634,051


Advance Monthly Sales

Consumer Price Index CPI

Producer Price Index PPI

Retail Inventories

Personal Income

Gross Domestic Product GDP

Money Supply

Industrial Production


Employment Situation

US International Trade

Factory Orders

Durable Goods

Construction Spending

Housing Starts

Vehicle Unit Sales


Event Calendar

DXLG's Profile

Stock Price

DXLG's Financials

Business Description


Charts & Quotes

DXLG's News


DXLG's Competitors

Customers & Markets

Economic Indicators

DXLG's Growth

Company Segments


Stock Performance

Growth Rates




Financial Strength


Largest Companies

Management Effectivness


At a Glance


Growth Rates



Financial Strength


At a Glance



Sectors & Industries






About us


Financial Terms

Technical Analysis

Fundamental Analysis

Energy Terms

Manufacturing Terms

Transportation Terms

Health Care

Insurance Terms

Economy Terms

Hotel & Leisure Terms

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.    Copyright © 2021 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
CSIMarket.com 1500 N. University Drive, Coral Springs, FL 33071